Variables | Cured (%) (n = 26) | Not cured # (%) (n = 20) | p value |
---|---|---|---|
Demographics | |||
Male sex | 19 (73.1) | 13 (65) | 0.75 |
Age >60 years | 6 (23.1) | 11 (55) | 0.04 |
Coexisting conditions | |||
AIDS | 2 (8.3) a | 4 (22.2) b | 0.38 |
Solid tumor malignancy | 2 (7.7) | 4 (20) | 0.38 |
Hematologic malignancy | 3 (11.5) | 1 (5) | 0.62 |
Steroid usage | 3 (11.5) | 5 (25) | 0.27 |
Liver cirrhosis | 1 (3.8) | 4 (20) | 0.37 |
Chronic renal failure | 2 (7.6) | 1 (5) | 1 |
Diabetic mellitus | 8 (30.8) | 4 (20) | 0.51 |
COPD | 4 (15.4) | 0 | 0.12 |
Organ transplantation | 1 (3.8) | 0 | 1 |
No known predisposing factor c | 6 (23.1) | 2 (10) | 0.44 |
Previous anti-fungal therapy d | 3 (11.5) | 4 (20) | 0.68 |
Severity status | |||
APACHE-II score | 8.2 ± 2.4 | 10.4 ± 3.7 | 0.19 |
APACHE-II score ≥ 15 | 5 (19.2) | 5 (25) | 0.73 |
Shock | 1 (3.8) | 0 | 1 |
IICP | 23 (88.5) | 18 (90) | 1 |
ICU admission | 14 (53.8) | 8 (40) | 0.39 |
Initial laboratory data | |||
India ink smear positive | 12 (46.2) | 11 (55) | 0.77 |
CSF opening pressure (mmH 2 0) | 248 ± 132 | 252 ± 136 | 0.58 |
CSF WBC count (/μL) | 32.2 ± 40.6 | 28.8 ± 38.6 | 0.28 |
CSF CAT ≥ 1:1024 | 13 (50) | 14 (70) | 0.23 |
Serum CAT ≥ 1:1024 | 9 (34.6) | 9 (45) | 0.55 |
Concurrent cryptococcemia | 6 (23.1) | 6 (30) | 0.74 |
Serotype B Cryptococcus neoformans isolate | 4 (15.4) | 1 (5) | 0.37 |
Isolate resistant to fluconazole (MIC >8 μg/ml) | 4 (15.4) | 8 (40) | 0.09 |
Isolate resistant to amphotericin B (MIC >1 μg/ml) | 3 (11.5) | 5 (25) | 0.27 |
Treatment modality in induction therapy | |||
Amphotericin B plus flucytosine | 0 | 1 (5) | 0.44 |
Amphotericin B plus fluconazole | 10 (38.5) | 13 (65) | 0.14 |
Amphotericin B alone | 12 (46.2) | 5 (25) | 0.22 |
Fluconazole alone | 4 (15.4) | 1 (5) | 0.37 |